Antiangiogenic drugs: Insights into drug development from endostatin, avastin and thalidomide

Molecular Interventions

Volumn 9, Issue 4, 2009, Pages 157-166

  Holaday, John W ^a,b   Berkowitz, Barry A ^a,c,d  

^a QRxPharma ^*

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOTHALIDOMIDE; 6 AMINOTHALIDOMIDE; AFLIBERCEPT; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANGIOZYME; BARBITURIC ACID DERIVATIVE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENDOSTAR; ENDOSTATIN; FLUOROURACIL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY DC101; RIDAFOROLIMUS; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VATALANIB; VINCA ALKALOID;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BIRTH DEFECT; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG DESIGN; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; LEPROSY; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; RETINA MACULA DEGENERATION; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; ENDOSTATINS; HISTORY, 20TH CENTURY; HUMANS; NEOPLASMS; THALIDOMIDE;

EID: 69749102520     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.4.2     Document Type: Review

References (38)

1. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Eng.l J. Med. 285, 1182-1186 (1971).
2. Klagsbrun, M., Sasse, J., Sullivan, R., and Smith, J.A. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA, 83, 2448-2452 (1986). (Pubitemid 16026900)
3. Adapted in part from materials of the Angiogenesis Foundation www.angio.org (accessed August 4, 2009).
4. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., and Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219, 983-985 (1983).
5. Ferrara, N. and Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 16, 851-858 (1989). (Pubitemid 19162712)
6. White, C.W., Sondheimer, H.M, Crouch, E.C., Wilson, H., and Fan L.L. Treatment of pulmonary hemangiomatosis with recombinant interferon Alpha-2a. N. Eng. J. Med. 320, 1197-1200 (1989). (Pubitemid 19124302)
7. Ingber, D., Fujita, T., Kishimoto, S., Katsuichi, S., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990). (Pubitemid 120015110)
8. Kim, K.J., Li B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., and Ferrara, N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo, Nature 362, 841-844 (1993). (Pubitemid 23132159)
9. Ferrara, N., Hillan, K.J., Gerber, H.P., and Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004). (Pubitemid 38618122)
10. Avastin (Genentech) www.gene.com/gene/products/information/oncology/ avastin/ (Accessed August 4, 2009).
11. Brem, H. and Folkman, J. Inhibition of tumor angiogenesis by cartilage. J. Exp. Med. 141, 427-439 (1975).
12. O'Reilly, M.S., Holmgren, L., Shing, Y. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994). (Pubitemid 24324921)
13. O'Reilly, M.S., Boehm, T., Shing, Y. et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285 (1997). (Pubitemid 28015876)
14. MacDonald, N.J., Shivers, W.Y., Narum, D.L.m et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J. Biol. Chem. 276, 25190-25196 (2001).
15. Beohm T., Folkman, J., Browder, T., and O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997). (Pubitemid 28027321)
16. Sim, K., Fogler, W.F., Zhou, X.H., Liang, H., Madsen, J.W., Luu, K., O'Reilly, M.S., Tomaszewski ,J.E., and Fortier, A.H. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3, 41-51 (1999). (Pubitemid 129644779)
17. Kolata, G.A. Cautious awe greets drugs that eradicate tumors in mice. New York Times A1-A3 (May 3, 1998).
18. King, R.P., Jr. Novel cancer approach from noted scientist hits stumbling block. Wall Street Journal A1-A8 (Nov 12, 1999).
19. NCI statement on animal studies of endostatin and angiostatin (May 4, 1998) www.nih.gov/news/pr/may98/nci-04.htm (Accessed August 4, 2009).
20. Dhanabal, M., Ramchandran, R., Volk, R., Stillman, I.E., Lombardo, M., Iruela-Arispe, M.L., Simons, M., and Sukhatme, V.P. Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59, 189-197 (1999). (Pubitemid 29062977)
21. Song, H-F., Liu, X-W, Zhang, H-N, Zhu, B-Z, Yuan, S-J, Liu, S-Y, and Tang, Z-M. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol. Sin. 26, 124-128 (2005).
22. D'Amato, R.J., Loughnan, M.S., Flynn, E., and Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082-4085 (1994).
23. Burkholz, H. Giving thalidomide a second chance. FDA Consumer Magazine. (September-October 1997).
24. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., and Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699-703 (1991).
25. Klausner, J.D., Freedman, V.H., and Kaplan, G. Thalidomide as an anti-TNF-α inhibitor: Implications for clinical use. Clin Immunol. Imunnother. 81, 19-23 (1996). (Pubitemid 26414548)
26. Fine, H.A., Figg, W.D., Jaeckle, K. et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18, 708-715 (2000). (Pubitemid 30106600)
27. Kerbel R.S., Yu J., Tran J., Man, S., Viloria-Petit A., Klement G., Coomber B.L., and Rak J. Possible mechanisms of acquired resistance to antiangiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metast. Rev. 20, 79-86 (2001). (Pubitemid 34074682)
28. Miller, K.D., Sweeney, C.J., and Sledge, G.W., Jr. The Snark is a Boojum: The continuing problem of drug resistance in the antiangiogenic era. Ann. Onco. 14, 20-28 (2003).
29. Bostrom, J., Shang-Fu, Y., Appleton, B.A. et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009).
30. Kerbel, R. and Folkman, J. Clinical translation of angiogenesis inhibitors Nat. Rev. Cancer 2, 727-739 (2002). (Pubitemid 37328908)
31. Shojaei, F., Wu, X, Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y.G., and Ferrara, N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. USA 106, 6742-6747 (2009).
32. Abdollahi, A., Hlatky, L., and Huber, P.E. Endostatin: The logic of antiangiogenic therapy. Drug Resist. Updat. 8, 59-74 (2005).
33. Parren, P.W. and Burton, D.R. Two-in-one designer antibodies. Science 323, 1567-1568 (2009).
34. Cooke, R. Dr Folkman's War: Angiogenesis and the Struggle to Defeat Cancer. Random House, New York (2001).
35. Berkowitz, B.A, and Sachs G Life cycle of a block buster: Discovery and development of omeprazole (Prilosec™). Mol. Interv. 2, 6-11 (2002).
36. Folkman, J. Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug. Discov. 6, 273-286 (2007).
37. Ferrara, N. Vascular endothelial growth factor. Arterioscler.Thromb. Vasc. Biol. 29, 789-791 (2009).
38. Folkman, J. Fighting cancer by attacking its blood supply. Sci. Am. 275, 150-154 (1996).